Beyond Air reported raising $1.38 Million in an initial SEC Form D filing, from an offering of $1.38 Million
PUBLIC · XAIRJun 28, 2023
Amount Raised
$1.38 Million
$1.38 Million sold, per SEC Form D (first sale Jun 15, 2023)
Round Type
Seed
Garden CityBiotechnologyHealthcareHealth Care
Quick answer
Beyond Air raised $1.38 Million in a Seed round, dated June 15, 2023. Beyond Air is based in Garden City, New York, United States.
How much did Beyond Air raise?
Beyond Air raised $1.38 Million in a Seed round on June 15, 2023.
What does Beyond Air do?
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory..
Where is Beyond Air based and how big is it?
Beyond Air is based in Garden City, New York, United States. Fundz records about 54 employees.
Who are the decision-makers at Beyond Air?
Fundz holds 2 contacts at Beyond Air, including the Chief Executive Officer & Owner. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who to call at Beyond Air, and when
A new round usually means Beyond Air is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Beyond Air raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Beyond Air, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Beyond Air. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Beyond Air
Location
Garden City, New York, United States
About
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Beyond Air raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.